---
title: Dehydroepiandrosterone Effects on HIV-1 Replication
nct_id: NCT00065104
overall_status: COMPLETED
phase: PHASE2
sponsor: National Center for Complementary and Integrative Health (NCCIH)
study_type: INTERVENTIONAL
primary_condition: HIV Infections
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00065104.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00065104"
ct_last_update_post_date: 2006-08-18
last_seen_at: "2026-05-12T06:40:58.184Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Dehydroepiandrosterone Effects on HIV-1 Replication

**NCT ID:** [NCT00065104](https://clinicaltrials.gov/study/NCT00065104)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** National Center for Complementary and Integrative Health (NCCIH)
- **Conditions:** HIV Infections
- **Start Date:** 2000-10
- **Completion Date:** 2003-04
- **CT.gov Last Update:** 2006-08-18

## Brief Summary

This study's purpose is to learn how dehydroepiandrosterone (DHEA) affects the HIV virus, the immune system, hormone levels, body composition and quality of life.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion criteria:

* Evidence of HIV-1 infection
* HIV RNA \<50 copies/mL
* Stable antiretroviral treatment regimen for at least 8 weeks
* Age 18 years or older
* Normal pap smear and mammograph within 1 year (females)
* Normal prostate-specific antigen level with in one year, age adjusted (males)

Exclusion criteria:

* Active opportunistic infections or malignancy other than localized cutaneous KS lesions
* Concurrent or prior use within the past 8 weeks of DHA, testosterone, other anabolic steroids, corticosteroids, megestrol acetate, growth hormone, IL-2, or thalidomide
* Diagnosis of AIDS Dementia Complex (stage II or higher)
* Active substance abuse (e.g., alcohol or injection drugs)
* Evidence of severe liver dysfunction or hepatic transaminases greater than 3x the upper normal limit
* Pregnant or breast-feeding
* History of endocrinologically-responsive tumors (e.g., breast, ovarian, uterine, or prostatic cancer, or malignant melanoma)
```

## Interventions

- **DHEA** (DRUG)

## Locations (1)

- Community Consortium, San Francisco, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.community consortium|san francisco|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00065104.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00065104*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*